100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
0 % Toleranz bei der Produktqualität
Lagerstandorte
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Vorbehaltlich Verfügbarkeit
Dokumentation
Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.
1797905-42-0Atorvastatin Diketo Amide 2-Fluoro Analog
● Auf Lager
| Katalog-Nr.:: | VE008630 |
|---|---|
| CAS-Nr.:: | 1797905-42-0 |
| Summenformel:: | C26H24FNO3 |
| Molare Masse:: | 417.47 g/mol |
Zusätzliche Informationen zu CAS 1797905-42-0
Parent drug
AtorvastatinIUPAC-Name
2-(2-(2-Fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxo-N-phenyl PentanamideSynonyme
N/ASMILES
CC(C)C(=O)C(C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2F)C(=O)NC3=CC=CC=C3Beschreibung
It is the oral antilipemic drug atorvastatin that reversibly inhibits HMG-CoA reductase. It raises plasma concentrations of HDL-C while decreasing levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), and triglyceride (TG). Atherosclerosis and cardiovascular disease are related to high LDL-C, low HDL-C, and high TG concentrations in the plasma. A major indicator of coronary artery disease is the ratio of total cholesterol to HDL-C, and greater ratios are linked to a higher risk of the condition. Lower cardiovascular risk is linked to higher HDL-C levels. A statin like atorvastatin lowers the risk of cardiovascular morbidity and death by lowering LDL-C and TG and raising HDL-C.References
McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 15 May 2022, www.ncbi.nlm.nih.gov/books/NBK430779/.Angebot anfordern
„*“ zeigt erforderliche Felder an
Other products related to Atorvastatin impurities
Verunreinigungsstruktur
Name der Muttersubstanz
CAS-Nr.:
Name der Verunreinigung
Katalog-Nr.:
